Most couples who need PGT-M already know something is coming. They’ve had a genetic counselling appointment, or watched a sibling live with a condition, or lost a child and the autopsy told them why. By the time someone explains the testing, there’s a weight in the room that clinical language isn’t really designed to hold.
PGT-M is not a routine fertility add-on. It’s a specific, technically demanding form of preimplantation genetic testing used when one or both partners carry a known single gene disorder, and the question on the table is whether that condition passes to a child. It requires months of preparation before an IVF cycle begins. It requires a genetics team working alongside a fertility team. And it requires a level of emotional processing that a standard consultation slot doesn’t accommodate.
This is what PGT-M involves, who it’s for, how it differs from PGT-A, what the process looks like from start to finish, and where its real limits are. Written for people already in this conversation, or who suspect they soon will be.
What PGT-M Is Actually Testing
PGT-A screens embryos for chromosomal abnormalities across all 23 chromosome pairs. It casts a wide net using a relatively standardised process. PGT-M does something more targeted and considerably more complex: it tests for a specific known mutation in a specific gene, using a custom-designed probe built around that couple’s particular DNA.
The PGT-M vs PGT-A difference is not just one of scope. It’s one of methodology. Single gene disorder IVF testing for PGT-M requires the laboratory to design a bespoke probe for each couple’s mutation, validate it against the couple’s DNA before the cycle starts, and then apply it to biopsy samples containing only a handful of cells. No two PGT-M cases are technically identical. That’s worth understanding before you assume it’s a simple add-on.
Conditions PGT-M can test for include sickle cell disease, thalassaemia, cystic fibrosis, Huntington’s disease, spinal muscular atrophy, BRCA1 and BRCA2 mutations, Duchenne muscular dystrophy, Fragile X syndrome, and myotonic dystrophy, among others. The list extends to any mutation that is known, characterised, and probeable. PGT-M finds what it’s specifically looking for. It does not do exploratory genetic mapping.
How It Differs From PGT-A in Practice
Patients ask whether both tests can be run simultaneously. Yes, and in many cases it’s the right call. PGT-M identifies embryos unaffected by the inherited condition. PGT-A additionally screens for chromosomal normality. In older patients especially, combining both means the embryo transferred is disease-free and chromosomally normal, addressing two independent causes of IVF failure in a single biopsy.
The preparation timeline is where they diverge most sharply. PGT-A can be added to an IVF cycle with relatively short notice. PGT-M cannot. The probe design and validation process, called workup, takes 2-4 months before the cycle begins. It requires DNA samples from both partners and frequently from an affected family member or a prior affected pregnancy. Without reference DNA, the probe cannot be validated.
This is the part of hereditary disease IVF screening in India that gets chronically underexplained. Couples who expect to start a cycle within weeks are consistently surprised to learn the preparation takes months. The timeline is not bureaucratic delay. It’s scientific necessity, and any clinic that suggests otherwise is cutting corners you don’t want cut.
Why Inheritance Patterns Matter
Not all single gene disorders carry the same risk structure, and the pattern shapes the clinical decision significantly.
Autosomal recessive conditions like sickle cell disease, cystic fibrosis, and thalassaemia require both partners to carry a mutation in the same gene for there to be reproductive risk. Two carriers have a 25% chance per pregnancy of an affected child. PGT-M for sickle cell disease is particularly relevant in India, where carrier frequencies are significantly higher than in Western populations, concentrated in central and eastern Indian states and specific communities. This is not a rare-disease problem in the Indian context. It’s a public health problem that fertility medicine can directly address, and it isn’t being addressed at anywhere near the scale it should be.
Autosomal dominant conditions like Huntington’s disease and certain BRCA mutations require only one mutated copy. A parent with Huntington’s passes it to 50% of children. PGT-M allows selection against the mutation before pregnancy, bypassing the alternative of prenatal diagnosis mid-pregnancy or, in the case of late-onset conditions, leaving the question unanswered entirely.
X-linked conditions like Duchenne muscular dystrophy affect males far more severely than females. Carrier mothers have a 50% chance of passing it to each son. PGT-M identifies affected male embryos before transfer.
Four Scenarios That Show What This Actually Looks Like
Consider four hypothetical profiles that show how PGT-M plays out across different clinical and ethical situations.
The first: a couple who are both carriers of sickle cell trait, identified through premarital screening. Their first child was born with sickle cell disease. In a case like this, PGT-M for sickle cell disease follows a defined path. DNA from both carriers is submitted to the genetics lab. Probe design and validation takes approximately 12-14 weeks. An IVF cycle retrieves multiple eggs; several reach blastocyst. PGT-M identifies unaffected embryos. Combined with PGT-A, the euploid unaffected embryo is selected for transfer. The resulting child does not have sickle cell disease. That outcome is not available through natural conception when both parents carry the mutation.
The second: a hypothetical 36-year-old who tests BRCA2 positive following a close family member’s cancer diagnosis. She wants to understand her options before starting a family. Can IVF with PGT-M mean her children don’t carry BRCA2? Yes, with important caveats. BRCA2 increases lifetime cancer risk substantially but does not cause disease in every carrier. Selecting against it in embryos involves values, not just medicine. Some people in this position feel strongly their children should have the choice. Others feel they are preventing a meaningful risk. Neither position is wrong. What is wrong is making that decision without proper genetic counselling, which is what some clinics allow because it shortens the pathway to starting a cycle.
The third: a couple in their early thirties, both of South Asian descent, who discover through carrier screening that both carry an SMA mutation with no family history. Each pregnancy without intervention carries a 25% chance of an affected child. PGT-M before their first pregnancy attempt is the logical path. Workup takes approximately ten weeks. A single IVF cycle produces blastocysts, of which unaffected euploid embryos are identified for transfer. This hypothetical represents the ideal use case for carrier screening followed by PGT-M: acting on information before a pregnancy is established rather than after.
The fourth: a hypothetical patient whose parent has Huntington’s disease and who has chosen not to undergo predictive genetic testing herself, not wanting to know her own status. She wants children but does not want to pass the Huntington’s mutation to them. This is where exclusion testing applies. Embryos are selected based on whether they inherited the chromosome from the at-risk parent, without ever revealing the parent’s own status. It is technically possible and ethically established. Most patients in this situation don’t know exclusion testing exists. That knowledge gap is a failure of how this field communicates, not a reflection of what’s available.
The Workup Phase, Concretely
Because PGT-M preparation is so consistently misunderstood, it’s worth being specific.
Genetic counselling happens first, before any laboratory work. Both partners meet a clinical geneticist who reviews the condition, the inheritance pattern, and the testing approach. This is not optional and not a formality. It is the foundation of informed consent, and any clinic that skips it to accelerate the timeline should be questioned.
DNA collection follows. Saliva or blood samples from both partners. If available, DNA from an affected family member or a prior affected pregnancy. The genetics lab uses this to design the custom probe.
Probe validation takes 6-12 weeks on average, longer for complex mutations. The probe is tested against the family DNA before any embryo is ever biopsied. This step cannot be rushed.
Then the IVF cycle: ovarian stimulation, egg retrieval, fertilisation via ICSI (used for all PGT cycles to prevent contamination of the biopsy sample), embryo culture to blastocyst.
Blastocysts are biopsied on day 5 or 6. Embryos are vitrified while results are processed, typically 2-3 weeks. Unaffected embryos are prioritised for transfer. If PGT-A was also run, euploid unaffected embryos come first.
What PGT-M Cannot Do
This needs saying clearly, and it rarely is.
PGT-M screens for what it’s designed to find. It does not screen for de novo mutations, spontaneous errors that aren’t inherited from either parent. It does not replace prenatal testing. Most specialists recommend confirmatory testing during the resulting pregnancy because no technology working with 5-8 cells from a biopsy has a zero error rate.
PGT-M also narrows the pool of transferable embryos. Some will be affected. Some will be aneuploid if PGT-A is run alongside. Some won’t reach blastocyst. For women with reduced ovarian reserve, the number available for testing may be limited from the start, and multiple stimulation cycles are sometimes needed before there are enough unaffected euploid embryos to work with.
None of this is a reason to avoid PGT-M. It’s a reason to go in with accurate expectations, which is a different thing.
The Access Gap in India
PGT-M is significantly underused in India relative to how many families carry mutations for sickle cell disease, beta thalassaemia, and SMA. India has among the highest carrier rates for haemoglobinopathies in the world. The barriers are awareness, cost, and a genuine shortage of centres with validated single gene disorder testing infrastructure.
Not every clinic that advertises PGT has PGT-M capability. Some offer PGT-A and list PGT-M on their website without the laboratory partnerships required to actually deliver it. The right question is not “do you offer PGT-M?” but “which genetics laboratory conducts your single gene disorder testing, and what is their validated experience with this specific mutation?” If the answer is vague, that’s your answer.
PGT-M treatment in Hyderabad at 9M Fertility is conducted in partnership with accredited genetics laboratories with validated protocols for single gene disorder testing. The workup timeline, probe design process, and realistic outcome range for your specific mutation are discussed before the cycle begins.
Genetic Disease Prevention Before Pregnancy Is Not a Guarantee. It’s as Close as Medicine Gets.
PGT-M shifts the odds dramatically in favour of an unaffected pregnancy using the most precise embryo selection technology currently available. It is not infallible. Confirmatory prenatal testing still matters. And there are cases where no unaffected embryos result from a cycle, which is one of the hardest outcomes this process can produce.
What PGT-M offers is the best available answer to a question that, without it, only gets answered mid-pregnancy or after birth. For couples who have already lived through an affected pregnancy, that earlier answer, even when it requires months of preparation and a demanding IVF cycle, is worth everything.
If you carry a hereditary condition and are thinking about starting a family, the conversation starts with a genetic counsellor and a fertility specialist together. Not one, then the other. Both, from the beginning.
Book a consultation at 9M Fertility.
→ Also read: PGT-A Testing: How Genetic Screening Can Improve Your IVF Success Rate
→ Also read: IVF vs ICSI: Which Fertility Treatment Is Right for You?
